Tuesday 27 September 2016

Report Analysis and Forecast on Pruritus-Pipeline Review, H2 2016

Pruritus-Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Pruritus pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.
To view the table of contents and know more details please visit Pruritus-Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pruritus
- The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
- The report assesses Pruritus therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pruritus
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pruritus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Albireo AB Alveonix AG Amorepacific Corporation Asana BioSciences, LLC Cara Therapeutics, Inc. Chugai Pharmaceutical Co., Ltd. Creabilis SA ELORAC, Inc. Faes Farma, S.A. GlaxoSmithKline Plc Hydra Biosciences, Inc. LEO Pharma A/S Merck & Co., Inc. NeRRe Therapeutics Ltd Nippon Shinyaku Co., Ltd. Patara Pharma, Inc. Phosphagenics Limited RDD Pharma Ltd. Sanwa Kagaku Kenkyusho Co., Ltd. Shionogi & Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Teikoku Pharma USA, Inc. Tioga Pharmaceuticals, Inc. Trevi Therapeutics, Inc. Vanda Pharmaceuticals Inc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home